Cargando…

Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review

Buruli ulcer (BU) is a cutaneous neglected tropical disease caused by Mycobacterium ulcerans. Synthesizing the evidence on their efficacy of antibiotic in the management of BU can help to better define their roles, identify weaknesses and inform clinicians on relevant measures than can be used to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Vouking, Marius Zambou, Tamo, Violette Claire, Tadenfok, Carine Nouboudem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880821/
https://www.ncbi.nlm.nih.gov/pubmed/24396561
http://dx.doi.org/10.11604/pamj.2013.15.155.2341
_version_ 1782298121059958784
author Vouking, Marius Zambou
Tamo, Violette Claire
Tadenfok, Carine Nouboudem
author_facet Vouking, Marius Zambou
Tamo, Violette Claire
Tadenfok, Carine Nouboudem
author_sort Vouking, Marius Zambou
collection PubMed
description Buruli ulcer (BU) is a cutaneous neglected tropical disease caused by Mycobacterium ulcerans. Synthesizing the evidence on their efficacy of antibiotic in the management of BU can help to better define their roles, identify weaknesses and inform clinicians on relevant measures than can be used to control BU. Our objectives is to assess the clinical efficacy of Rifampicin-Streptomycin given for 8 weeks of treatment of early M. ulcerans infection. We searched the following electronic databases from January 2005 to July 2012: Medline, EMBASE (Excerpta Medica Database), The Cochrane Library, Google Scholar, CINAHL (Cumulative Index to Nursing and Allied Health Literature), WHOLIS (World Health Organization Library Database), LILACS (Latin American and Caribbean Literature on Health Sciences) and contacted experts in the field. There were no restrictions to language or publication status. All study designs that could provide the information we sought for were eligible provided the studies were conducted in the third world. Critical appraisal of all identified citations was done independently by three authors to establish the possible relevance of the articles for inclusion in the review. Of the 115 studies, 09 papers met the inclusion criteria. The duration of treatment ranged from 8 to 48 weeks depending on the severity. Oral chemotherapy alone obtained a curative rate of 50%. The “dual” mode of treatment (surgery + chemotherapy) reduced hospital admission period from 90 to 39.8 days, that's to 44.2%. This treatment for early stages could therefore replace surgery and in severe cases, is an indispensable aid before surgery. These results confirmed that the daily administration of Rifampicin and Streptomycin is an effective treatment for M. ulcerans infection in an early stage. Subsequent systematic reviews should be conducted to determine if antibiotics could heal injuries without resorting to surgery and to compare different treatment durations.
format Online
Article
Text
id pubmed-3880821
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-38808212014-01-06 Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review Vouking, Marius Zambou Tamo, Violette Claire Tadenfok, Carine Nouboudem Pan Afr Med J Review Buruli ulcer (BU) is a cutaneous neglected tropical disease caused by Mycobacterium ulcerans. Synthesizing the evidence on their efficacy of antibiotic in the management of BU can help to better define their roles, identify weaknesses and inform clinicians on relevant measures than can be used to control BU. Our objectives is to assess the clinical efficacy of Rifampicin-Streptomycin given for 8 weeks of treatment of early M. ulcerans infection. We searched the following electronic databases from January 2005 to July 2012: Medline, EMBASE (Excerpta Medica Database), The Cochrane Library, Google Scholar, CINAHL (Cumulative Index to Nursing and Allied Health Literature), WHOLIS (World Health Organization Library Database), LILACS (Latin American and Caribbean Literature on Health Sciences) and contacted experts in the field. There were no restrictions to language or publication status. All study designs that could provide the information we sought for were eligible provided the studies were conducted in the third world. Critical appraisal of all identified citations was done independently by three authors to establish the possible relevance of the articles for inclusion in the review. Of the 115 studies, 09 papers met the inclusion criteria. The duration of treatment ranged from 8 to 48 weeks depending on the severity. Oral chemotherapy alone obtained a curative rate of 50%. The “dual” mode of treatment (surgery + chemotherapy) reduced hospital admission period from 90 to 39.8 days, that's to 44.2%. This treatment for early stages could therefore replace surgery and in severe cases, is an indispensable aid before surgery. These results confirmed that the daily administration of Rifampicin and Streptomycin is an effective treatment for M. ulcerans infection in an early stage. Subsequent systematic reviews should be conducted to determine if antibiotics could heal injuries without resorting to surgery and to compare different treatment durations. The African Field Epidemiology Network 2013-08-29 /pmc/articles/PMC3880821/ /pubmed/24396561 http://dx.doi.org/10.11604/pamj.2013.15.155.2341 Text en © Marius Zambou Vouking et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Vouking, Marius Zambou
Tamo, Violette Claire
Tadenfok, Carine Nouboudem
Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title_full Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title_fullStr Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title_full_unstemmed Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title_short Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review
title_sort clinical efficacy of rifampicin and streptomycin in combination against mycobacterium ulcerans infection: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880821/
https://www.ncbi.nlm.nih.gov/pubmed/24396561
http://dx.doi.org/10.11604/pamj.2013.15.155.2341
work_keys_str_mv AT voukingmariuszambou clinicalefficacyofrifampicinandstreptomycinincombinationagainstmycobacteriumulceransinfectionasystematicreview
AT tamovioletteclaire clinicalefficacyofrifampicinandstreptomycinincombinationagainstmycobacteriumulceransinfectionasystematicreview
AT tadenfokcarinenouboudem clinicalefficacyofrifampicinandstreptomycinincombinationagainstmycobacteriumulceransinfectionasystematicreview